Dr. Ryan A. Wilcox

Rajen Mody is a Hematologist and an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Mody is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Infantile Neutropenia, Glioma, and Bone Marrow Aspiration.

Dr. Dale Bixby has been practicing hematology at the University of Michigan since 2009. He obtained his PhD in Medicinal Chemistry and Pharmaceutics at the University of Kentucky in 1999, before beginning his medical training at the University of Michigan in Ann Arbor, MI. He was a resident in the Department of Internal Medicine and then completed fellowship training in hematology and medical oncology at the University of Michigan. Dr. Bixby is currently a clinical professor and specializes in the areas of myeloid and lymphoid leukemias, myelodysplastic syndrome and bone marrow failure disorders. Dr. Bixby currently serves as the section chief of the acute leukemia program. He is also a clinical investigator in hematological malignancies. Dr. Bixby is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Chronic Myelogenous Leukemia (CML), and Bone Marrow Aspiration. Dr. Bixby is board certified in Hematology.

Dr. Sahai is the Leader of the Gastrointestinal Medical Oncology Section and Associate Professor in the Division of Hematology-Oncology, Department of Internal Medicine. Dr. Sahai is also a member of the University of Michigan Rogel Cancer Center and Director of Tumor Response Assessment Core.Dr. Sahai attended medical school at the Government Medical College at Amritsar with the Baba Farid University of Health Science in India. He then completed his Masters in Clinical Epidemiology at Harvard School of Public Health followed by Internal Medicine residency training at University of Pittsburgh where he met his wife. He completed his fellowship in Hematology-Oncology at Northwestern University where he also served as the Chief Fellow. Subsequently, Dr. Sahai joined University of Michigan as Assistant Professor in Internal Medicine in 2013.Dr. Sahai is a clinician-scientist who sees patients within the Multidisciplinary Pancreatic and Liver Tumor programs. As a clinical investigator he is the Principal Investigator on several investigator-initiated clinical trials open across the U.S. His translational research program leverages the pancreaticobiliary cancer biobanks that he directs for the therapeutic investigation of novel compounds in patient-derived cell lines and xenograft models to help develop novel phase 1/2 investigator-initiated clinical trials. Dr. Sahai is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Cancer, Familial Pancreatic Cancer, and Neuroendocrine Tumor.